Chemed Corporation (NYSE:CHE) Receives Consensus Rating of “Hold” from Analysts

Chemed Corporation (NYSE:CHE) has been assigned a consensus rating of “Hold” from the six analysts that are currently covering the company, MarketBeat reports. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $501.50.

A number of research firms have issued reports on CHE. Weiss Ratings upgraded shares of Chemed from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, April 29th. Royal Bank Of Canada lifted their target price on shares of Chemed from $422.00 to $436.00 and gave the company a “sector perform” rating in a research note on Monday, April 27th. Wall Street Zen cut shares of Chemed from a “buy” rating to a “hold” rating in a research note on Monday. Zacks Research upgraded shares of Chemed from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Finally, Oppenheimer reduced their price objective on shares of Chemed from $580.00 to $500.00 and set an “outperform” rating for the company in a research note on Friday, February 27th.

Chemed Price Performance

NYSE CHE opened at $446.85 on Wednesday. The company has a quick ratio of 0.83, a current ratio of 0.85 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $5.93 billion, a PE ratio of 24.35, a price-to-earnings-growth ratio of 1.65 and a beta of 0.54. The company has a 50 day moving average price of $412.34 and a two-hundred day moving average price of $424.66. Chemed has a 12-month low of $365.20 and a 12-month high of $562.77.

Chemed (NYSE:CHE) last posted its earnings results on Thursday, April 23rd. The company reported $5.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.30 by $0.35. The firm had revenue of $657.51 million during the quarter, compared to analysts’ expectations of $659.22 million. Chemed had a net margin of 10.23% and a return on equity of 27.18%. The company’s revenue was up 1.6% compared to the same quarter last year. During the same period in the previous year, the company earned $5.63 earnings per share. Chemed has set its FY 2026 guidance at 24.000-24.75 EPS. As a group, equities analysts predict that Chemed will post 22.3 earnings per share for the current fiscal year.

Chemed Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 16th. Shareholders of record on Thursday, May 28th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Thursday, May 28th. This represents a $2.40 dividend on an annualized basis and a yield of 0.5%. Chemed’s payout ratio is currently 13.08%.

Insiders Place Their Bets

In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $421.13, for a total transaction of $842,260.00. Following the completion of the transaction, the chief executive officer owned 90,219 shares of the company’s stock, valued at $37,993,927.47. The trade was a 2.17% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 3.33% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Maripau Wealth Management LLC lifted its position in Chemed by 5.4% during the 1st quarter. Maripau Wealth Management LLC now owns 970 shares of the company’s stock worth $366,000 after acquiring an additional 50 shares during the last quarter. Segall Bryant & Hamill LLC acquired a new position in Chemed during the 1st quarter worth $2,293,000. Cim LLC lifted its position in Chemed by 1.6% during the 1st quarter. Cim LLC now owns 2,325 shares of the company’s stock worth $878,000 after acquiring an additional 37 shares during the last quarter. Amundi lifted its position in Chemed by 6,982.7% during the 1st quarter. Amundi now owns 35,555 shares of the company’s stock worth $13,431,000 after acquiring an additional 35,053 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its position in Chemed by 9.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 406 shares of the company’s stock worth $153,000 after acquiring an additional 35 shares during the last quarter. Institutional investors and hedge funds own 95.85% of the company’s stock.

Chemed Company Profile

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.